Evidence map›Paper›PMID 17638875›Full record

ArticleCancer research2007

Cancer cells and normal cells differ in their requirements for Thoc1.

Yanping Li, Athena W Lin, Xiaojing Zhang, Yanqing Wang, Xiaoling Wang, David W Goodrich

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. The Thoc1 ribonucleoprotein and prostate cancer progression.Journal of the National Cancer Institute · 2014
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yanping LiRoswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
Athena W Lin
Xiaojing Zhang
Yanqing Wang
Xiaoling Wang
David W Goodrich
Roswell Park Comprehensive Cancer Center · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
Requirements for Normal Rb Function In VivoR01CA070292 · NCI · UNIVERSITY OF TEXAS MD ANDERSON CAN CTR · PI GOODRICH, DAVID W. · 1996 to 2010
$2.9M
The Role of Thoc1 in Normal Development and CancerR01CA125665 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI GOODRICH, DAVID W. · 2007 to 2011
$1.8M
NCI NIH HHS CA 016056NCI NIH HHS CA 125665NCI NIH HHS CA 70292NCI NIH HHS P30 CA016056NCI NIH HHS R01 CA125665
6 · The paper itself

Abstract

The evolutionarily conserved TREX (Transcription/Export) complex physically couples transcription, messenger ribonucleoprotein particle biogenesis, RNA processing, and RNA export for a subset of genes. HPR1 encodes an essential component of the S. cerevisiae TREX complex. HPR1 loss compromises transcriptional elongation, nuclear RNA export, and genome stability. Yet, HPR1 is not required for yeast viability. Thoc1 is the recently discovered human functional orthologue of HPR1. Thoc1 is expressed at higher levels in breast cancer than in normal epithelia, and expression levels correlate with tumor size and metastatic potential. Depletion of Thoc1 protein (pThoc1) in human cancer cell lines compromises cell proliferation. It is currently unclear whether Thoc1 is essential for all mammalian cells or whether cancer cells may differ from normal cells in their dependence on Thoc1. To address this issue, we have compared the requirements for Thoc1 in the proliferation and survival of isogenic normal and oncogene-transformed cells. Neoplastic cells rapidly lose viability via apoptotic cell death on depletion of pThoc1. Induction of apoptotic cell death is coincident with increased DNA damage as indicated by the appearance of phosphorylated histone H2AX. In contrast, the viability of normal cells is largely unaffected by pThoc1 loss. Normal cells lacking Thoc1 cannot be transformed by forced expression of E1A and Ha-ras, suggesting that Thoc1 may be important for neoplastic transformation. In sum, our data are consistent with the hypothesis that cancer cells require higher levels of pThoc1 for survival than normal cells. If true, pThoc1 may provide a novel molecular target for cancer therapy.

Indexed as

Gene Expression Regulation, NeoplasticApoptosisCell Cycle ProteinsCell Line, TumorCell SurvivalCell Transformation, NeoplasticDNA-Binding ProteinsDNA DamageEvolution, MolecularFibroblastsGenomeHeLa CellsHumansModels, BiologicalNeoplasm MetastasisNuclear ProteinsCell Cycle ProteinsDNA-Binding ProteinsNuclear ProteinsRNA-Binding ProteinsTHOC1 protein, human

Identifiers

PMID17638875
PMCPMC2804983
OpenAlexW1994302443

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.